anpac_logo_full color_stacked.png
AnPac Bio Announces Filing of Annual Report on Form 20-F for 2020
30 avr. 2021 16h45 HE | Anpac Bio, USA
SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (NASDAQ: ANPC) (“AnPac Bio” or the “Company”), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Reports Fiscal Year 2020 Annual Financial Results (89.1% Increase in Revenue and 20.7% Decrease in Net Loss)
30 avr. 2021 08h00 HE | Anpac Bio, USA
SAN JOSE, Calif., April 30, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
22157.jpg
Next Generation Cancer Diagnostics Market Report 2021: Global Next Generation Cancer Diagnostics Market to Grow $15,738.27 Million by 2025, at a CAGR of 22.54%
23 avr. 2021 05h03 HE | Research and Markets
Dublin, April 23, 2021 (GLOBE NEWSWIRE) -- The "Next Generation Cancer Diagnostics Market Research Report by Technology, by Cancer Type, by Function, by Application - Global Forecast to 2025 -...
anpac_logo_full color_stacked.png
AnPac Bio Reports Record Q1 for Paid CDA-Based Cancer Testing Volume in 2021, Increasing Approximately 130% Compared to Q1, 2020
16 avr. 2021 16h15 HE | Anpac Bio, USA
SAN JOSE, Calif., April 16, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
anpac_logo_full color_stacked.png
AnPac Bio Developed and Completed Evaluations of New Generation Cancer Detection Sensor with Improved Performance
09 mars 2021 07h30 HE | Anpac Bio, USA
SAN JOSE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
AnPac Bio Regains Compliance with Nasdaq Continued Listing Requirement
05 mars 2021 16h35 HE | Anpac Bio, USA
SAN JOSE, Calif., March 05, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
anpac_logo_full color_stacked.png
China’s NMPA Approved Starting of Registration Testing of AnPac Bio Class III Medical Device (For Lung Cancer Auxiliary Diagnosis Utility)
08 févr. 2021 07h00 HE | Anpac Bio, USA
SAN JOSE, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United...
22157.jpg
Cervical Cancer Screening Market, 2026 - Patients, Mortality Forecast by Tests Type -Pap Smear, HPV DNA, VIA
08 févr. 2021 04h18 HE | Research and Markets
Dublin, Feb. 08, 2021 (GLOBE NEWSWIRE) -- The "Cervical Cancer Screening Market, Patients, Mortality Global Forecast by Tests Type (Pap Smear, HPV DNA, VIA), 19 Countries Analysis" report has been...
anpac_logo_full color_stacked.png
AnPac Bio Granted a New US patent on Novel Medical Device for Multi-Cancer Detection
01 févr. 2021 07h30 HE | Anpac Bio, USA
SAN JOSE, Calif., Feb. 01, 2021 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the...
22157.jpg
Global Cervical Cancer Diagnostic Testing Devices Pipeline Assessment 2020: Developments, Products, Company Product Overview, Recent Developments
24 déc. 2020 05h18 HE | Research and Markets
Dublin, Dec. 24, 2020 (GLOBE NEWSWIRE) -- The "Cervical Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2020" report has been added to ResearchAndMarkets.com's offering. "Cervical...